Clinical Trials Logo
  1. Home
  2. Sars-CoV2
  3. NCT04592510

Impact of COVID-19 on Pediatric Dental Practice During First, Second And Third Wave.

SARS-CoV2 Clinical Trial

Official title:
Impact of COVID-19 on Pediatric Dental Practice During First, Second And Third Wave Among a Group of Pediatric Dentists : A Cross -Sectional Study

Clinical Trial Summary

Assessment of impact of covid-19 on pediatric dental practice during first, second and third wave among a group of pediatric dentists.

Clinical Trial Description

On the 11th of March, 2020, COVID-19 (SARS-CoV-2) was declared as a pandemic by the World Health Organization. SARS-CoV-2 is an unpredictable virus that is rapidly transmitting from one country to another, and unfortunately as of today, there is no effective medication or vaccine for the disease control. This virus has gone on to cause one of the most rapidly expanding pandemics with over 9 million people being infected worldwide including the pediatric population. Due to the unique nature of dentistry, most dental procedures generate significant amounts of droplets and aerosols, posing potential risks of infection transmission. Recent studies have demonstrated the role of the oral mucosa in COVID-19 infection, in addition to expressing the ACE2 receptor in salivary glands in the asymptomatic process in infected saliva, thus being one of the main sources of viruses. Clinical features of COVID-19 in children include fever and cough, but a large proportion of infected children appears to be asymptomatic and may contribute significantly to transmission. Therefore, it can be assumed that, at this stage in the pandemic, all children and their parents/carers are potentially infective with the potential of cross-infection to dental stuff, parents and the public. This has, in theory, an impact on medical and dental procedures that are Aerosol Generating Procedures. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04592510
Study type Observational
Source Cairo University
Contact Fatma Essam El-Deen
Phone 01150035515
Email fatma_essam@dentistry.cu.edu.eg
Status Recruiting
Phase
Start date May 25, 2021
Completion date January 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04446065 - Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers Phase 2/Phase 3
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Not yet recruiting NCT04400019 - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Phase 2/Phase 3
Completed NCT04463004 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Phase 2
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2
Recruiting NCT04581148 - SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
Recruiting NCT04441372 - Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Completed NCT04530604 - Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS) Phase 1
Active, not recruiting NCT04635605 - Methylene Blue Treatment of COVID-19 Phase 2
Recruiting NCT04395599 - Risk of Air Contamination During Visceral Surgery in COVID19 Patients N/A
Recruiting NCT04472585 - Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients Phase 1/Phase 2
Active, not recruiting NCT04411433 - Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 Phase 3
Completed NCT04359706 - Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
Recruiting NCT04395794 - SARS-CoV-2 Disguise Study
Completed NCT04386551 - Detection of COVID-19 in Saliva Collection
Recruiting NCT04403269 - NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE Phase 2
Withdrawn NCT04379492 - A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 Phase 2
Completed NCT04407182 - Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19 Phase 2